RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
RHB-104-04
Phase 3 small_molecule completed
Quick answer
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) for Crohn Disease is a Phase 3 program (small_molecule) at RedHill Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RedHill Biopharma
- Indication
- Crohn Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed